Saving time in medical research means saving lives. That’s the theme of a new social media campaign by FasterCures, designed to elevate the profile of medical research on the national agenda and underscore the toll of a slow, inefficient research system on every life. Through personal stories and compelling graphics, Time=Lives explains why medical research matters.
Legislation co-sponsored by Representatives Brian Bilbray (R-CA), Carolyn Maloney (D-NY) and Rosa DeLauro (D-CT), and supported by the Melanoma Research Foundation, seeks to encourage the development of so-called “significant drug combinations” by offering the carrot of an extension of marketing exclusivity.
By Laura Welch
I am a 33-year-old mother of a 2-year-old boy and wife to a wonderful US Soldier. In July 2011 we moved from Seattle to DC. Hello sunshine!
On August 18, 2011, I was diagnosed with Epitheliod Sarcoma (ES), a rare and aggressive form of cancer. I did what anyone in this day and age would do; I consulted the bible that is Google! The prognosis was bleak, to put it mildly. However, I am of the mindset that if this disease is so rare that it has little data available, I will make my own data and try not to dwell on the figures in front of me.
ACT UP and their colleagues fought for nine years before winning life-saving medications. They organized a mass movement, they took to the streets, they made art, they made noise, they made a difference. Their tools included clear demands, arresting graphics, media savvy, and an ability to learn from their mistakes and refine their strategies. And a sense of humor, when appropriate, in combination with their urgent and ethical message.
The POLITICO Pro Health care team takes an in-depth look at the future and policies of the FDA. Special guests include: Friends of Cancer Research’s Dr. Jeff Allen; The Pew Charitable Health Group’s Allan Coukell; Biotechnology Industry Organization’s Sara Radcliffe and the FDA’s Dr. Janet Woodcock.
On September 25, 2012, the President’s Council of Advisors on Science and Technology (“PCAST”) released a report entitled “Report to the President on Propelling Innovation in Drug Discovery, Development, and Evaluation.”
Christopher P. Austin, M.D., named director of NCATS
The mission of the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) is to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions.
Rare disease advocate says the focus should be on ensuring the accelerated approval expansion and surrogate endpoint guidances become FDA priorities as the rare disease drug program is set to grow under PDUFA V.
Regulatory Update / Article # 00120917013
Congress mandated specific upgrades to FDA’s rare disease program in the new user fee legislation, but the largest impact may come through the expected changes to the accelerated approval pathway.
BY ELIZABETH M. WROE & PHILIP S. BONFORTE
The threat of a delayed or deterred (re-)authorization of key Food and Drug Administration (FDA) user fee programs (hereinafter referred to as the ‘‘FDA user fees’’) caused significant angst among biomedical product stakeholders over the course of the last year and a half.
Washington • Of all the Utahns elected as delegates to the Democratic National Convention, Jamie Hartley is the outlier. She isn’t a party insider or union leader, a politician or a campaign strategist.
Hartley has no real political experience at all.
But as a Utah County resident struggling with a painful genetic disorder she’s very familiar with the nation’s medical system, and that’s something she wants to bring to the big political gathering in Charlotte, N.C.